Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626. doi:10.1093/eurheartj/ehad194
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 3;79(17):1757-1780. doi: 10.1016/j.jacc.2021.12.011. Epub 2022 Apr 1. PMID: 35379504.
McDonald M, Virani S, Chan M, et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol [Internet]. 2021 Apr;37(4):531-546. doi: 10.1016/j.cjca.2021.01.017. PMID: 33827756.
Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021 Mar 1;S1071-9164(21)00050-6. doi: 10.1016/j.cardfail.2021.01.022. PMID: 33663906.
McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021 Dec 21;42(48):4901. PMID: 34447992.
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020 Dec 22;76(25):e159-e240. doi: 10.1016/j.jacc.2020.08.045. Epub 2020 Nov 20. PMID: 33229116.
Bozkurt B, Colvin M, Cook J, et al; American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation. 2016 Dec 6;134(23):e579-e646. Epub 2016 Nov 3. Erratum in: Circulation. 2016 Dec 6;134(23):e652. PMID: 27832612.
WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016 Sep 27;134(13):e282-93. doi: 10.1161/CIR.0000000000000435. Epub 2016 May 20. Erratum in: Circulation. 2016 Sep 27;134(13):e298. PMID: 27208050.
Ponikowski P, Voors AA, Anker SD, et al; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. Erratum in: Eur Heart J. 2016 Dec 30. PMID: 27206819.
Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015 May 7;36(18):1090-7. doi: 10.1093/eurheartj/ehv009. Epub 2015 Jan 29. Review. PMID: 25636745; PMCID: PMC4422973.
Definition and ClassificationTop
Cardiomyopathies are myocardial disorders in which the myocardium is structurally and functionally abnormal in the absence of significant coronary artery disease, hypertension, valvular heart disease, or congenital heart disease. These 4 conditions can cause left ventricular (LV) dysfunction from ischemia, infarction, volume overload, or pressure overload and are excluded from the classification scheme of cardiomyopathies by the European Society of Cardiology and the American Heart Association.
While classification schemes vary, cardiomyopathies are typically classified according to morphologic phenotypes, which can be further divided into familial or nonfamilial forms:
1) Dilated cardiomyopathy (DCM).
2) Hypertrophic cardiomyopathy (HCM).
3) Restrictive cardiomyopathy (RCM).
4) Arrhythmogenic right ventricular cardiomyopathy (ARVC).
5) Nondilated left ventricular cardiomyopathy (NDLVC).
6) Unclassified cardiomyopathy.
The diagnosis of cardiomyopathies has several limitations. For this reason the European Society of Cardiology described a new category of cardiomyopathies characterized by the presence of nonischemic LV scarring or fatty replacement, regardless of the LV function and without LV dilatation. Such patients should now be classified as having NDLVC.
Each of the above 6 types of cardiomyopathies can be further classified as:
1) Familial (genetic) cardiomyopathy: Occurrence in ≥1 family member of a phenotype caused by the same genetic mutation or a de novo mutation in an index patient that can be transmitted to offspring, which is seen in Mendelian inheritance. There is also evidence of polygenic inheritance, where multiple genetic variants can determine susceptibility to a phenotype.
2) Nonfamilial (nongenetic) cardiomyopathy: Either idiopathic (of an unknown cause) or acquired (associated with toxins, infections, other diseases).